TRIM59在结直肠癌中的表达及其与临床病理指标的关系

doi:10.3969/j.issn.1004-616x.2021.06.008

Abstract

Abstract: OBJECTIVE: To investigate expression of tripartite motif-containing 59 (TRIM59) in colorectal cancer and its correlation with clinicopathological features. METHODS: Colorectal cancers and adjacent tissues were collected; and expressions of TRIM59 were analyzed using real-time quantitative PCR(qPCR) and immunohistochemistry. Relationships between TRIM59 expressions and clinicopathological features and survival rates were analyzed. RESULTS: Results from the qPCR analyses on 86 cases of pair tissues showed that expression levels of TRIM59 in 20 cases were significantly higher than that in the paired adjacent tissues (t=12.86,P<0.01). Immunohistochemical results showed that positive expression rate of TRIM59 was 62.79% (54/86),which was significantly higher than 32% (37/86) in the adjacent tissues (χ²=6.74,P=0.009)。The high expression of TRIM59 was significantly correlated with TNM stages (χ²=8.515,P=0.003),tumor invasion depths (χ²=7.167,P=0.007) and lymph node metastases (χ²=5.511,P=0.018). Kaplan-Meier survival analyses showed that the overall survival (OS) and disease-free survival (DFS) of patients with high TRIM59 expression were significantly shorter than those of patients with low TRIM59 expression (P<0.05 both). CONCLUSION: TRIM59 was highly expressed in colorectal cancers and the high expressions were closely related to TNM stages,depth of invasions,lymph node metastases and prognosis.

Key words: tripartite motif-containing 59, colorectal cancer, clinicopathological features, prognosis

CLC Number:

R730.2

GAO Xiaobin, WU Xueliang, WANG Shengjie, SUN Guangyuan, WANG Wenjing, LIANG Feng, ZHAO Yifeng, LIU Zhenxian, ZHANG Yingchun. Expression of TRIM59 and its correlations with clinicopathological features in colorectal cancers[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 446-450.

References

[1] DEKKER E, TANIS P J, VLEUGELS J L A, et al. Colorectal cancer[J]. Lancet, 2019, 394(10207):1467-1480.
[2] THANIKACHALAM K, KHAN G. Colorectal cancer and nutrition[J]. Nutrients, 2019, 11(1):164.
[3] WROBEL P, AHMED S. Current status of immunotherapy in metastatic colorectal cancer[J]. Int J Colorectal Dis, 2019, 34(1):13-25.
[4] ARAN V, VICTORINO A P, THULER L C, et al. Colorectal cancer:epidemiology, disease mechanisms and interventions to reduce onset and mortality[J]. Clin Colorectal Cancer, 2016, 15(3):195-203.
[5] XUE L, WILLIAMSON A, GAINES S, et al. An update on colorectal cancer[J]. Curr Probl Surg, 2018, 55(3):76-116.
[6] IJSSELSTEIJN M E, SANZ-PAMPLONA R, HERMITTE F, et al. Colorectal cancer:a paradigmatic model for cancer immunology and immunotherapy[J]. Mol Aspects Med, 2019, 69:123-129.
[7] HU S H, ZHAO M J, WANG W X, et al. TRIM59 is a key regulator of growth and migration inrenal cell carcinoma[J]. Cell Mol Biol Noisy Le Grand France, 2017, 63(5):68-74.
[8] TAN P, YE Y Q, HE L, et al. TRIM59 promotes breast cancer motility by suppressing p62-selective autophagic degradation of PDCD10[J]. PLoS Biol, 2018, 16(11):e3000051.
[9] LI R, WENG L, LIU B, et al. TRIM59 predicts poor prognosis and promotes pancreatic cancer progression via the PI3K/AKT/mTOR-glycolysis signaling axis[J]. J Cell Biochem, 2020, 121(2):1986-1997.
[10] SUN G, SUI X, HAN D, et al. TRIM59 promotes cell proliferation, migration and invasion in human hepatocellular carcinoma cells[J]. Pharmazie, 2017, 72(11):674-679.
[11] TAN P, HE L, ZHOU Y. TRIM59 deficiency curtails breast cancer metastasis through SQSTM1-selective autophagic degradation of PDCD10[J]. Autophagy, 2019, 15(4):747-749.
[12] VALIYEVA F, JIANG F, ELMAADAWI A, et al. Characterization of the oncogenic activity of the novel TRIM59 gene in mouse cancer models[J]. Mol Cancer Ther, 2011, 10(7):1229-1240.
[13] LIANG M, CHEN X, WANG L, et al. Cancer-derived exosomal TRIM59 regulates macrophage NLRP3 inflammasome activation to promote lung cancer progression[J]. J Exp Clin Cancer Res, 2020, 39(1):176.
[14] LIU G M, SONG J Y, ZHAO Y, et al. Tripartite motif containing 59(TRIM59) promotes esophageal cancer progression via promoting MST4 expression and ERK pathway[J]. J Recept Signal Transduct Res, 2020, 40(5):471-478.
[15] HAN T, GUO M, GAN M, et al. TRIM59 regulates autophagy through modulating both the transcription and the ubiquitination of BECN1[J]. Autophagy, 2018, 14(12):2035-2048.
[16] TAN P, YE Y, HE L, et al. TRIM59 promotes breast cancer motility by suppressing p62-selective autophagic degradation of PDCD10[J]. PLoS Biol, 2018, 16(11):e3000051.
[17] WANG Y, ZHOU Z, WANG X, et al. TRIM59 is a novel marker of poor prognosis and promotes malignant progression of ovarian cancer by inducing annexin A2 expression[J]. Int J Biol Sci, 2018, 14(14):2073-2082.
[18] HAO L, DU B, XI X. TRIM59 is a novel potential prognostic biomarker in patients with non-small cell lung cancer:a research based on bioinformatics analysis[J]. Oncol Lett, 2017, 14(2):2153-2164.
[19] LI R, WENG L, LIU B, et al. TRIM59 predicts poor prognosis and promotes pancreatic cancer progression via the PI3K/AKT/mTOR-glycolysis signaling axis[J]. J Cell Biochem, 2020, 121(2):1986-1997.
[20] ZHOU Z, JI Z, WANG Y, et al. TRIM59 is up-regulated in gastric tumors, promoting ubiquitination and degradation of p53[J]. Gastroenterology, 2014, 147(5):1043-1054.

Expression of TRIM59 and its correlations with clinicopathological features in colorectal cancers

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	XUE Song, HU Jiahai, DONG Xiangning. Expression of PGAM5 and its association with clinicopathologic characteristics in pancreatic cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 29-34.
[2]	WANG Kefang, CHEN Yu, WU Chenyu, LIU Mei, WANG Lijie, TIAN Jianguang, ZHOU Xiaohui, XU Lan. Clinicopathological roles of IL-17A and estrogen receptors α, β in epithelial ovarian cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 42-47.
[3]	ZHU Wenbiao, QIU bo, XIE Shoucheng, XIAO Huanqin, LIU Gaomin. Expression and clinical significance of transmembrane protein 79 in hepatocellular carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 426-430.
[4]	YANG Shangying, HUANG Mingxiang, XU Dexin, LIU Jiafu, CHEN Xinfu. Expression of DNAJB4 and association with immune infiltration and prognosis in non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 467-472.
[5]	GUO Wenjing, DENG Hui, SONG Ping, ZHANG Mengxian. Expression and biological functions of TGFBI in glioma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(5): 341-348.
[6]	WEI Laifeng, HONG Chaoqun, CHEN Liuyi, XU Yiwei, WU Fangcai. Prognostic value of nomogram of laboratory inflammation-related indicators in tongue squamous cell carcinoma patients with surgery [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(5): 366-373.
[7]	YANG Chengqing, CUI Yonghui, ZHENG Ziheng. Expression and clinical significance of miR-653-5p in colon cancer patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(4): 261-265.
[8]	LIU Ruixue, ZHANG Liwei. Expression and significance of AMPK esophageal squamous cell carcinoma among Kazakhs [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(4): 285-291.
[9]	HUANG Mengpan, WANG Xuehong, LU Yongfu. Expression and clinical significance of TNF-α and FOXA2 in patients with colorectal cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(4): 296-301,324.
[10]	WANG Na, WANG Ping, HE Yijia, ZENG Jing, HAN Congling, WANG Sirui, XUAN Xiaoyan. Bioinformatic analysis of immune cell infiltration and tumor mutation burden in colorectal cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 172-177.
[11]	LIU Ying, WANG Rui, GUO Xiao, DONG Lüli, ZHANG Yan, ZHAO Yinhuan, DU Yun. Relationships between DNA ploidy abnormality and EGFR mutation in pleural effusions, and their effects on prognosis of lung adenocarcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 178-182,186.
[12]	WANG Ping, WANG Huayong, WANG Hao, LEI Dajun. Expression of miR-193a and miR-21-5p in serum exosomes from osteosarcoma patients and their clinical values [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 197-201.
[13]	HUANG Lidan, WU Yueming, WANG Yadi, TAN Qi. Relationships between VEGF-A protein expression and EGFR mutation in patients with lung adenocarcinomas and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(2): 116-120.
[14]	TAN Jianhua, LAI Yaozhen, TANG Lihua, ZHOU Li. Efficacy and prognostic values of two treatments for advanced epithelial ovarian cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(2): 131-138.
[15]	HU Xueyi, SHEN Feng, WU Lun, SU Caiwu, WEI Jian. SPON2 expression in papillary thyroid carcinomas and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(1): 9-14.